-
Je něco špatně v tomto záznamu ?
MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients
J. Kovacova, J. Juracek, A. Poprach, J. Kopecky, O. Fiala, M. Svoboda, P. Fabian, L. Radova, P. Brabec, T. Buchler, O. Slaby,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2004 do Před 2 roky
PubMed Central
od 2016
Europe PubMed Central
od 2016
PubMed
31467229
DOI
10.21873/cgp.20140
Knihovny.cz E-zdroje
- MeSH
- karcinom z renálních buněk farmakoterapie patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- mikro RNA genetika MeSH
- protinádorové látky farmakologie terapeutické užití MeSH
- senioři MeSH
- sunitinib farmakologie terapeutické užití MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND/AIM: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. PATIENTS AND METHODS: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. RESULTS: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). CONCLUSION: A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.
Institute for Biostatistics and Analyses Masaryk University Brno Czech Republic
Masaryk University Central European Institute of Technology Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005967
- 003
- CZ-PrNML
- 005
- 20200526134046.0
- 007
- ta
- 008
- 200511s2019 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/cgp.20140 $2 doi
- 035 __
- $a (PubMed)31467229
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Kovacova, Julia $u Masaryk University, Central European Institute of Technology, Brno, Czech Republic.
- 245 10
- $a MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients / $c J. Kovacova, J. Juracek, A. Poprach, J. Kopecky, O. Fiala, M. Svoboda, P. Fabian, L. Radova, P. Brabec, T. Buchler, O. Slaby,
- 520 9_
- $a BACKGROUND/AIM: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. PATIENTS AND METHODS: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. RESULTS: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). CONCLUSION: A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a sunitinib $x farmakologie $x terapeutické užití $7 D000077210
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Juracek, Jaroslav $u Masaryk University, Central European Institute of Technology, Brno, Czech Republic.
- 700 1_
- $a Poprach, Alexandr $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
- 700 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Svoboda, Marek $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Fabian, Pavel $u Masaryk Memorial Cancer Institute, Department of Oncological and Experimental Pathology Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Radova, Lenka $u Masaryk University, Central European Institute of Technology, Brno, Czech Republic.
- 700 1_
- $a Brabec, Petr $u Institute for Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Slaby, Ondrej $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic on.slaby@gmail.com.
- 773 0_
- $w MED00180194 $t Cancer genomics & proteomics $x 1790-6245 $g Roč. 16, č. 5 (2019), s. 353-359
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31467229 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200526134042 $b ABA008
- 999 __
- $a ok $b bmc $g 1524825 $s 1096023
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 16 $c 5 $d 353-359 $e - $i 1790-6245 $m Cancer genomics & proteomics $n Cancer Genomics Proteomics $x MED00180194
- LZP __
- $a Pubmed-20200511